Kostas Biliouris
Stock Analyst at Oppenheimer
(1.09)
# 3,855
Out of 5,115 analysts
63
Total ratings
34%
Success rate
-14.41%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTA Centessa Pharmaceuticals | Maintains: Outperform | $40 → $62 | $25.68 | +141.43% | 7 | Dec 10, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $50 | $22.32 | +124.01% | 9 | Sep 22, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $450 → $470 | $400.69 | +17.30% | 6 | Sep 8, 2025 | |
| IONS Ionis Pharmaceuticals | Upgrades: Outperform | $40 → $70 | $80.65 | -13.21% | 3 | Sep 3, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Market Perform | $15 → $4 | $1.83 | +118.58% | 1 | Jul 8, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $30 → $8 | $3.51 | +127.92% | 2 | May 28, 2025 | |
| RNA Avidity Biosciences | Initiates: Outperform | $72 | $72.20 | -0.27% | 1 | Mar 12, 2025 | |
| DYN Dyne Therapeutics | Initiates: Outperform | $50 | $20.37 | +145.46% | 1 | Mar 12, 2025 | |
| SLN Silence Therapeutics | Maintains: Outperform | $67 → $25 | $6.26 | +299.36% | 2 | Mar 4, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $70 → $50 | $9.59 | +421.38% | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $4.26 | +698.12% | 3 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $17 | $1.74 | +877.01% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $40 | $8.08 | +395.05% | 4 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 | $22.98 | +291.64% | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $8.41 | +1,326.87% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 | $28.14 | +102.56% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $37 | $76.53 | -51.65% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $100 | $60.16 | +66.22% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $3.57 | +432.21% | 1 | Oct 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $98 | $56.71 | +72.81% | 1 | Jun 17, 2022 |
Centessa Pharmaceuticals
Dec 10, 2025
Maintains: Outperform
Price Target: $40 → $62
Current: $25.68
Upside: +141.43%
Sarepta Therapeutics
Sep 22, 2025
Upgrades: Outperform
Price Target: $50
Current: $22.32
Upside: +124.01%
Alnylam Pharmaceuticals
Sep 8, 2025
Maintains: Outperform
Price Target: $450 → $470
Current: $400.69
Upside: +17.30%
Ionis Pharmaceuticals
Sep 3, 2025
Upgrades: Outperform
Price Target: $40 → $70
Current: $80.65
Upside: -13.21%
Jasper Therapeutics
Jul 8, 2025
Downgrades: Market Perform
Price Target: $15 → $4
Current: $1.83
Upside: +118.58%
Rocket Pharmaceuticals
May 28, 2025
Maintains: Outperform
Price Target: $30 → $8
Current: $3.51
Upside: +127.92%
Avidity Biosciences
Mar 12, 2025
Initiates: Outperform
Price Target: $72
Current: $72.20
Upside: -0.27%
Dyne Therapeutics
Mar 12, 2025
Initiates: Outperform
Price Target: $50
Current: $20.37
Upside: +145.46%
Silence Therapeutics
Mar 4, 2025
Maintains: Outperform
Price Target: $67 → $25
Current: $6.26
Upside: +299.36%
Intellia Therapeutics
Jan 10, 2025
Maintains: Outperform
Price Target: $70 → $50
Current: $9.59
Upside: +421.38%
Jan 10, 2025
Upgrades: Outperform
Price Target: $34
Current: $4.26
Upside: +698.12%
Aug 15, 2024
Maintains: Outperform
Price Target: $22 → $17
Current: $1.74
Upside: +877.01%
Jul 18, 2024
Maintains: Outperform
Price Target: $63 → $40
Current: $8.08
Upside: +395.05%
Jul 3, 2024
Maintains: Outperform
Price Target: $90
Current: $22.98
Upside: +291.64%
May 15, 2024
Maintains: Outperform
Price Target: $120
Current: $8.41
Upside: +1,326.87%
Mar 27, 2024
Maintains: Outperform
Price Target: $57
Current: $28.14
Upside: +102.56%
Jan 31, 2024
Initiates: Market Perform
Price Target: $37
Current: $76.53
Upside: -51.65%
Nov 3, 2023
Maintains: Outperform
Price Target: $102 → $100
Current: $60.16
Upside: +66.22%
Oct 9, 2023
Initiates: Outperform
Price Target: $19
Current: $3.57
Upside: +432.21%
Jun 17, 2022
Initiates: Outperform
Price Target: $98
Current: $56.71
Upside: +72.81%